CNST - Constellation Pharmaceuticals appoints new chief commercial officer

Constellation Pharmaceuticals ([[CNST]] +5.4%) appoints Brendan Delaney to the newly created position of Chief Commercial Officer, effective January 11, 2021. In this role, Mr. Delaney will be responsible for building and leading the company’s commercial organization and pre-launch preparations in support of CPI-0610, which has the potential to be a disease-modifying therapy for patients living with myelofibrosis.“Brendan is joining Constellation at a pivotal time, and I look forward to working with him to advance the treatment paradigm for patients with myelofibrosis. With more than 25 years of experience in hematology and oncology commercialization, Brendan’s expertise will be invaluable as we prepare for the potential launch of our first product, CPI-0610—the first potential new myelofibrosis therapy beyond JAK inhibitors.” said Jigar Raythatha, President and CEO.

For further details see:

Constellation Pharmaceuticals appoints new chief commercial officer